Edrecolomab
Source: Wikipedia, the free encyclopedia.
Monoclonal antibody
EpCAM (17-1A) | |
|---|---|
| Clinical data | |
| Trade names | Panorex |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived
EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas
.
Preliminary studies had shown promise of a possible use in patients with stage III
lymph nodes).[1][2] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.[3]
Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.
References
Monoclonal antibodies for tumors | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor |
| ||||||||||||
| |||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
drug article is a stub. You can help Wikipedia by expanding it. |